Tirapazamine and DNA Damage in Tumor Cells
Author Information
Author(s): BG Siim, PL van Zijl, JM Brown
Primary Institution: Stanford University School of Medicine
Hypothesis
Can the comet assay predict the response of individual tumors to tirapazamine based on DNA damage?
Conclusion
The study found a strong correlation between tirapazamine-induced DNA damage and its cytotoxic effects on hypoxic tumor cells.
Supporting Evidence
- The correlation between hypoxic cytotoxic potency of tirapazamine and DNA damage was highly significant (r=0.905, P=0.013).
- Tirapazamine exhibits high hypoxia-selective cytotoxicity in the order of 50 to 200-fold in most rodent and human cell lines.
- The study suggests that the comet assay may be used as a predictive assay for tumor response to tirapazamine.
Takeaway
This study shows that measuring DNA damage can help predict how well a cancer drug called tirapazamine will work on different tumors.
Methodology
The study used the comet assay to measure DNA damage and high-performance liquid chromatography (HPLC) to analyze drug metabolism in various tumor cell lines under hypoxic conditions.
Limitations
The study was limited to a small number of cell lines and may not represent all tumor types.
Statistical Information
P-Value
0.013
Statistical Significance
p=0.013
Want to read the original?
Access the complete publication on the publisher's website